Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

CEO

Mr. Richard F. Pops

Employees

1800

Country

United States

ISIN

IE00B56GVS15

Listings

0 Comments

Share your thoughts

FAQ

What is Alkermes stock price today?▼

The current price of ALKS is $45.23 USD — it has increased by +2.59% in the past 24 hours. Watch Alkermes stock price performance more closely on the chart.

What is Alkermes stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Alkermes stocks are traded under the ticker ALKS.

Is Alkermes stock price growing?▼

ALKS stock has risen by +3.33% compared to the previous week, the month change is a +20.86% rise, over the last year Alkermes has showed a +52.17% increase.

What is Alkermes market cap?▼

Today Alkermes has the market capitalization of 7.54B

When is the next Alkermes earnings date?▼

Alkermes is going to release the next earnings report on July 29, 2026.

What were Alkermes earnings last quarter?▼

ALKS earnings for the last quarter are -0.4 USD per share, whereas the estimation was -0.55 USD resulting in a +26.74% surprise. The estimated earnings for the next quarter are N/A USD per share.

What is Alkermes revenue for the last year?▼

Alkermes revenue for the last year amounts to 2.95B USD.

What is Alkermes net income for the last year?▼

ALKS net income for the last year is 483.33M USD.

How many employees does Alkermes have?▼

As of June 17, 2026, the company has 1,800 employees.

In which sector is Alkermes located?▼

Alkermes operates in the Health & Wellness sector.

When did Alkermes complete a stock split?▼

The last stock split for Alkermes was on May 15, 2000 with a ratio of 2:1.

Where is Alkermes headquartered?▼

Alkermes is headquartered in Dublin, United States.